ADMA Biologics Inc (ADMA)

[Viewmont]

ADMA Receives Department of Health and Human Services U.S. License
RAMSEY, N.J. and BOCA RATON, Fla., April 02, 2019 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA” or the “Company”), a vertically integrated commercial biopharmaceutical and specialty immunoglobulin company that manufactures, markets and develops plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases, announces that the U.S. Food and Drug Administration (“FDA”) has issued a Department of Health and Human Services U.S. license No. 2019 to the Company in connection with the approval of ASCENIV™ Immune Globulin Intravenous, Human – slra 10% Liquid.

The license covers the Boca Raton, FL manufacturing facility which has demonstrated compliance with FDA requirements as well as authorizes ADMA to manufacture and enter into interstate commerce with ASCENIV™.